Market Research Logo

Global Prostate Cancer Diagnostics & Therapy Market - Segmented by Type, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Global Prostate Cancer Diagnostics & Therapy Market - Segmented by Type, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)

The prostate cancer diagnostics market is expected to witness a CAGR of 6.1% during the forecast period (2018-2023). North America was leading the global market with the largest revenue share in 2016.

High Prevalence Rate of Prostate Cancer

The high prevalence rate of prostate cancer is a key factor, which is driving the global market for the prostate cancer. Prostate cancer is the second-leading cause of death in the United States. According to National Cancer Institute, it is estimated that there were around 161,360 new cases of prostate cancer and an estimated 26,730 people will die due to it. Based on these statistics, we can see that the prevalence rate of prostate cancer is increasing across the world and hence, it is driving the market.

The other factors include innovation in drugs and developments in genomics and proteomics, rise in the funding in both public and private sectors, in the field of drug development, technological advancement in oncology diagnostics and therapeutics area.

Increasing Cost of the Prostate Cancer Drugs

There are many new drugs that have increased the life expectancy of prostate cancer patients and have been approved by the Food & Drug Administration. But these drugs are having a high cost, which is a threat for the patients and the insurers, both. These expensive drugs are not being paid by the insurance companies and the reimbursement level for them is very low. Hence, only few people are capable of affording these drugs. Therefore, because of this high cost, the use of generic drugs is more, and hence, it is hindering the growth of the prostate cancer drugs market.

The other factors include, low success rate of clinical trials and side effects of the treatments.

The United States Dominates the Market

North America is the leading global market with the largest revenue share in 2016. Due to the rising prevalence of the diseases and high mortality rate of the prostate cancer in the United States, North America is dominating the market. Asia-Pacific is also projected to be the fastest growing region, due to the improving healthcare infrastructure and the growing investments by the key market players.

Key Developments in the Market

  • February 2017: AstraZeneca entered into an agreement with TerSera Therapeutics LLC, for Zoladex in the United States and Canada. Zoladex is an injectable luteinising hormone-releasing agonist, which is used to treat prostate cancer, breast cancer, and certain benign gynaecological disorders.

Reasons to Purchase this Report
  • Current and future market outlook for prostate cancer diagnostics, in the developed and emerging markets
  • Analyze various perspectives on the market, with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 months analyst support, along with the market estimate sheet ((in Excel).
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 High Disease Prevalence Rate of Prostate Cancer
6.1.2 Innovation in Drugs and Developments in Genomics and Proteomics
6.1.3 Rise in the Funding in Both Public and Private Sector in the Field of Drug Development
6.1.4 Technological Advancement in Oncology Diagnostics & Therapeutics Area
6.2 Market Restraints
6.2.1 High Cost Associated with Diagnostic Tests
6.2.2 Low Success Rate of Clinical Trials
6.2.3 Side Effects of Treatments
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Type
7.1.1 Benign Prostatic Hyperplasia
7.1.2 Prostatic Adenocarcinoma
7.1.3 Small Cell Carcinoma
7.1.4 Others
7.2 By Diagnosis
7.2.1 Tissue Biopsy
7.2.2 Digital Rectal Examination Transrectal Ultrasound Transrectal Ultrasonography
7.2.3 Clinical Laboratory Examination Prostate-Specific Antigen Testing Urine Testing Blood Testing
7.2.4 Diagnostic Imaging
7.3 By Treatment
7.3.1 Chemotherapy
7.3.2 Brachytherapy
7.3.3 Radiation therapy
7.4 By Geography
7.4.1 North America United States Canada Mexico
7.4.2 Europe France Germany United Kingdom Italy Spain Rest of Europe
7.4.3 Asia-pacific China Japan India Australia & New Zealand South Korea Rest of Asia-Pacific
7.4.4 Middle East & Africa GCC South Africa Rest of the Middle East & Africa
7.4.5 South America Brazil Argentina Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott
9.2 AstraZeneca
9.3 Astellas Pharma Inc
9.4 Bayer AG
9.5 BioMark Diagnostics Inc.
9.6 Sanofi
9.7 Ipsen
9.8 TOLMAR Pharmaceuticals, Inc.
9.9 Indevus Pharmaceuticals Inc.
9.10 Dendreon Inc.
9.10 List Not Exhaustive
10. Future of the Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report